- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.10. | Gain Therapeutics, Inc.: Gain Therapeutics to Attend the 2025 Maxim Growth Summit | 4 | GlobeNewswire (USA) | ||
| 14.10. | Gain Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.10. | Gain Therapeutics, Inc.: Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease | 2 | GlobeNewswire (USA) | ||
| 06.10. | Gain Therapeutics meldet vorläufige Phase-1b-Daten für Parkinson-Medikament GT-02287 | 2 | Investing.com Deutsch | ||
| 06.10. | Gain Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.10. | Gain Therapeutics reports positive early data from Parkinson's trial | 1 | Investing.com | ||
| 06.10. | Gain Therapeutics, Inc.: Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders | 3 | GlobeNewswire (USA) | ||
| GAIN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 23.09. | Gain Therapeutics, Inc.: Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025 | 2 | GlobeNewswire (USA) | ||
| 18.09. | Gain Therapeutics extends Phase 1b Parkinson's treatment study | 2 | Investing.com | ||
| 18.09. | Gain Therapeutics, Inc.: Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease | 102 | GlobeNewswire (Europe) | Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an additional nine months after completing the first 90-day dosing schedule The Phase 1b study enrolled... ► Artikel lesen | |
| 25.08. | H.C. Wainwright reiterates Buy rating on Gain Therapeutics stock at $8 price target | 2 | Investing.com | ||
| 25.08. | BTIG lowers Gain Therapeutics stock price target to $9 on biomarker data timing | 2 | Investing.com | ||
| 12.08. | Gain Therapeutics, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 12.08. | Gain Therapeutics GAAP EPS of -$0.19 misses by $0.02 | 1 | Seeking Alpha | ||
| 17.07. | Gain Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.07. | Gain Therapeutics, Inc.: Gain Therapeutics Announces Pricing of $7.0 Million Public Offering | 2 | GlobeNewswire (USA) | ||
| 15.07. | Gain Therapeutics stock falls after announcing public offering | 2 | Investing.com | ||
| 15.07. | Gain Therapeutics announces proposed public offering | 1 | Seeking Alpha | ||
| 15.07. | Gain Therapeutics-Aktie fällt nach Ankündigung einer Kapitalerhöhung | 3 | Investing.com Deutsch | ||
| 15.07. | Gain Therapeutics, Inc.: Gain Therapeutics Announces Proposed Public Offering | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NUVALENT | 93,39 | +2,75 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| QIAGEN | 42,405 | +0,32 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 66,06 | -3,25 % | Tarsus Pharmaceuticals stock price target raised to $88 from $72 at H.C. Wainwright | ||
| INHIBRX BIOSCIENCES | 57,29 | +102,01 % | Morning Market Movers: Picard Medical, Qualigen Therapeutics, Inhibrx Biosciences, MidWestOne Financial GroupSee Big Swings | BEIJING (dpa-AFX) - At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ARVINAS | 9,210 | +0,66 % | Arvinas reports promising preclinical data for KRAS G12D cancer drug | ||
| NEUPHORIA THERAPEUTICS | 6,260 | +55,34 % | Morning Market Movers: AlphaVest Acquisition Corp., Neuphoria Therapeutics, BranchOut Food, rYojbaba See Big Swings | BEIJING (dpa-AFX) - At 7:35 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,040 | +5,59 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
| EVOTEC | 6,972 | +1,54 % | Aktien Frankfurt: Solide Zahlen aus den USA schieben Kurse an | FRANKFURT (dpa-AFX) - Überwiegend robuste Quartalsbilanzen und Prognosen von US-Unternehmen haben dem deutschen Aktienmarkt am Dienstag etwas Anschub verliehen. Der Leitindex Dax, der sich bis zum... ► Artikel lesen | |
| ADMA BIOLOGICS | 15,170 | -0,52 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 39,900 | -2,21 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
| NURIX THERAPEUTICS | 11,090 | +6,63 % | Nurix Therapeutics, Inc.: Nurix Initiates DAYBreak Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia | 600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 5,805 | -11,91 % | Ventyx Biosciences: NBC feiert Daten-Knall und +928% in 6 Monaten | Der Party-Herbst reißt nicht ab: Nach dem Tenbagger Minerva explodieren im No Brainer Club die nächsten Kurs-Granaten. Eine davon ist die Aktie von Ventyx Biosciences. Die Ventyx-Aktie hatte der No... ► Artikel lesen | |
| JANUX THERAPEUTICS | 24,900 | +1,80 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
| 89BIO | 14,785 | -0,10 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 11,340 | +13,40 % | 4D Molecular Therapeutics stock maintains Outperform rating at RBC Capital |
Das Unternehmen GAIN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,975 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GAIN THERAPEUTICS INC finden Sie auf Wallstreet Online.